GLP-1 每個月要多少錢？長期下來呢？
What Does GLP-1 Actually Cost? And Over Time?
在美國，GLP-1 與雙效腸泌素針劑的自費月費用相當可觀。以 2024–2025 年的標準定價來看：
In the United States, the out-of-pocket monthly cost of GLP-1 and dual-agonist injectables is substantial. Based on 2024–2025 pricing:
美國每月自費均價
US avg. monthly self-pay
美國每月自費均價
US avg. monthly self-pay
累積費用（美元估算）
of continuous medication
關鍵問題在於：GLP-1 藥物的作用取決於持續用藥。停藥後，體重在 12–18 個月內幾乎回到原點。這意味著，若要維持效果，就必須無限期投入費用——沒有終點。
The critical issue: GLP-1 medication requires continuous use. After stopping, weight returns to near baseline within 12–18 months. Maintaining the effect means an open-ended financial commitment with no endpoint.
以 10 年為單位估算：每月 $1,200 美元 × 120 個月 = $144,000 美元的累積費用，且這筆錢買到的是「持續壓制食慾的效果」，一旦停藥，效果消失，體重回升。
Over a 10-year horizon: $1,200/month × 120 months = $144,000 USD — buying an effect that disappears the moment you stop paying.
手術是一次性投資，效益長達 10 年以上
Surgery Is a One-Time Investment With 10+ Years of Return
2025 年發表於 JAMA Surgery 的大型真實世界研究（n = 30,458），直接比較了代謝手術與 GLP-1 藥物治療的 2 年費用與效果：
A major 2025 real-world study in JAMA Surgery (n = 30,458) directly compared 2-year costs and outcomes of metabolic surgery vs. GLP-1 medication:
（約 31 公斤）
2-year weight loss (~69 lbs)
（約 11 公斤）
2-year weight loss (~25 lbs)
後續醫療費用（美元）
over 2 years (USD)
📌 10.3% 跟藥廠說的 15–22% 差很多——為什麼？
臨床試驗（STEP-1、SURMOUNT-1）的高減重率，是在嚴格篩選、高依從性受試者中所得，與現實用藥差距甚大。
真實世界中，約 53% 的患者在 1 年內停藥，2 年累積停藥率達 72%，原因包括費用、副作用與保險中斷。一旦將所有真實患者（包含提早停藥者）納入整體分析，族群平均減重降至約 10.3%——仍比臨床試驗數據低 30–50%。這才是大多數患者實際面對的數字。
📌 Why 10.3%? Pharma trials reported 15–22% — what's the gap?
Trial results come from highly selected, closely monitored participants with near-perfect adherence — far from routine clinical practice.
In the real world, ~53% stop GLP-1 within 1 year and ~72% by 2 years due to cost, side effects, and insurance interruptions. When all real-world patients (including early discontinuers) are included, the population-level average drops to ~10.3% — still 30–50% below clinical trial benchmarks. This is what the evidence shows for most patients in practice.
換句話說：手術的減重效果是 GLP-1 的近 3 倍，且 2 年後在後續醫療費用上就已節省近 1.2 萬美元。加計手術本身的一次性費用後，總費用在 3–5 年內通常就與持續用藥拉平，之後每一年都是手術組在省錢。
Surgery delivers nearly 3× the weight loss of GLP-1, and within 2 years saves nearly $12,000 in follow-on medical costs. Accounting for the one-time surgical cost, total expenditure typically equalises at 3–5 years — after which surgery patients save money every year.
費用累積試算（美元概估）
Cumulative Cost Estimate (USD, approximate)
*上述費用為概估，實際金額依保險覆蓋範圍、個人用藥劑量及手術類型而有所差異。
*Figures are approximate estimates. Actual amounts vary by insurance coverage, dosage, and procedure type.
BMI 偏高的患者：藥物往往達不到健康目標體重
For High-BMI Patients: Medication Often Can't Reach a Healthy Target Weight
以一位 BMI 42、體重 110 公斤的患者為例：
Consider a patient with BMI 42, weighing 110 kg:
GLP-1 藥物帶來的平均減重（~5%），往往仍落在代謝疾病的高風險範圍內。手術帶來的 24–30% 減重，才是讓多數患者脫離高風險 BMI 區間、同時改善血糖、血壓、血脂的關鍵幅度。
GLP-1's average ~5% weight reduction often keeps patients within a high metabolic risk BMI range. Surgery's 24–30% reduction is what moves most high-BMI patients out of the high-risk zone while simultaneously improving blood glucose, blood pressure, and lipids.
哪些 BMI 族群符合手術評估資格？
Which BMI Groups Are Eligible for Surgical Evaluation?
根據 2022 年 ASMBS/IFSO 最新指引，代謝手術的適應症已較以往更寬鬆：
According to the 2022 ASMBS/IFSO updated guidelines, eligibility criteria for metabolic surgery are now broader than before:
| BMI 範圍 | BMI Range | 條件 | Condition | 建議 | Recommendation |
|---|---|---|---|---|---|
| ≥ 40 | 不需共病 | No comorbidities required | 明確建議手術Recommended | ||
| 35–39.9 | 合併代謝疾病（糖尿病、高血壓、血脂異常、睡眠呼吸中止等） | With metabolic comorbidity (diabetes, hypertension, dyslipidaemia, sleep apnea) | 明確建議手術Recommended | ||
| 30–34.9 | 合併代謝疾病，尤其是第 2 型糖尿病 | With metabolic disease, especially type 2 diabetes | 可評估手術Consider evaluation |
符合 BMI 條件只是評估的起點，而非終點。醫師會綜合考量體重趨勢、共病嚴重程度、藥物治療反應、患者意願與手術風險，才給出個人化建議。建議與專科醫師進行完整的初診評估。
Meeting BMI criteria is the starting point for evaluation, not a mandate for surgery. Your doctor will weigh weight trajectory, comorbidity severity, medication response, patient preference, and surgical risk together before making a personalised recommendation. A comprehensive specialist consultation is the right first step.
關於費用與效益，最常被問到的 4 個問題
4 Most Common Questions About Cost and Effectiveness
GLP-1 藥物的費用，台灣和美國一樣貴嗎？
Are GLP-1 costs the same in Taiwan as in the US?
目前台灣的 GLP-1 針劑（如 Ozempic、Mounjaro）為自費藥物，月費用約為 8,000–20,000 元新台幣，依劑量與廠商而異。本文引用的美國數據（$1,000–1,400/月）是目前全球最高的自費定價，各地區實際費用不同，但「長期用藥 vs. 一次性手術」的效益邏輯在各市場均適用。
In Taiwan, GLP-1 injectables (Ozempic, Mounjaro etc.) are currently self-pay, running approximately NT$8,000–20,000/month depending on dose and brand. The US figures cited ($1,000–1,400/month) represent the highest self-pay prices globally; local costs vary, but the "ongoing medication vs. one-time surgery" value argument applies across markets.
代謝手術本身費用大概多少？台灣需要自費嗎？
How much does metabolic surgery cost in Taiwan?
在台灣，符合健保規定的患者（BMI ≥ 37.5，或 BMI ≥ 32.5 合併第二型糖尿病、高血壓、睡眠呼吸中止症等高危險代謝共病）可申請健保給付，自費負擔相對較低。不符合健保標準但仍有手術適應症的患者，則需全自費，費用依術式及醫院而定。詳細費用建議直接向門診詢問，因個案狀況不同而有所差異。
In Taiwan, patients who meet NHI criteria (BMI ≥ 37.5, or BMI ≥ 32.5 with high-risk metabolic comorbidities such as Type 2 diabetes, hypertension, or obstructive sleep apnea) may qualify for NHI coverage, significantly reducing out-of-pocket costs. Those outside NHI criteria but still eligible for surgery pay privately, with costs varying by procedure and hospital. Please inquire directly at the clinic for a personalised estimate.
我已經在用 GLP-1 有效果，還需要考慮手術嗎？
GLP-1 is working for me — do I still need to consider surgery?
如果 GLP-1 效果良好，且已達到理想的健康體重目標，持續藥物治療是合理的選擇。但若你的起始 BMI 偏高（≥ 35 或 ≥ 40），藥物帶來的初期減重往往在距離目標體重還有很大差距時就停滯——這時手術可以接棒，延伸减重幅度，並提供不依賴持續用藥的長期效果。
If GLP-1 is working well and you've reached a healthy target weight, continuing medication is a reasonable choice. However, if your starting BMI is elevated (≥35/40), medication-driven weight loss often plateaus well before reaching target — surgery can take over, extending weight reduction and providing long-term results that don't depend on ongoing injections.
手術之後還需要打 GLP-1 嗎？費用又怎麼算？
Will I need GLP-1 after surgery? What about costs?
多數患者術後對 GLP-1 的需求大幅降低，甚至完全不需要。手術本身改變了腸道荷爾蒙分泌模式，達到部分 GLP-1 的效果——但更持久且不需要持續費用。少數患者在術後體重停滯時，會以較低劑量 GLP-1 輔助，費用也相對較低。整體而言，術後的藥物費用通常顯著低於術前的持續用藥費用。
Most patients dramatically reduce or eliminate GLP-1 use after surgery. The procedure itself reshapes gut hormone patterns, achieving some of GLP-1's effects durably and without ongoing cost. A minority of patients use low-dose GLP-1 adjunctively post-operatively, at significantly lower doses and costs. Overall, post-surgical medication costs are typically far lower than pre-surgical continuous GLP-1 use.
想了解你的手術適應症與費用？
Want to Evaluate Your Eligibility and Costs?
林育弘醫師的門診提供完整的初診評估，包含 BMI 分析、共病評估、術式建議與健保申請資格確認。歡迎掛號或私訊諮詢。
Dr. Yu-Hung Lin's clinic provides a comprehensive initial evaluation including BMI analysis, comorbidity assessment, procedure recommendation, and NHI eligibility review. Book an appointment or message us to start.
📚 參考文獻
📚 References
- Bariatric Surgery vs. GLP-1 RAs — large real-world cohort (n = 30,458). JAMA Surgery. 2025. ASMBS Summary
- Head-to-head Study: Bariatric Surgery Superior to GLP-1 Drugs for Weight Loss. ASMBS 2025 Annual Scientific Meeting. ASMBS Press Release
- Bariatric surgery tied to higher weight loss than Wegovy, Zepbound in real-world setting. Healio. 2026. Healio
- Aronne LJ et al. SURMOUNT-4: Weight regain after tirzepatide discontinuation. 2024–2025. ACC.org
- Eisenberg D et al. 2022 ASMBS/IFSO Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022. PubMed 36336720
- Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. PMC. 2025. PMC12444648